Related Experiment Video
Updated: Oct 15, 2026

Three Different Protocols of Corneal Collagen Crosslinking in Keratoconus: Conventional, Accelerated and Iontophoresis
Published on: November 12, 2015
Topical ciprofloxacin for bacterial corneal ulcer
P Kosrirukvongs1, W Buranapongs
1Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Objective:
To assess topical ciprofloxacin in patients with moderate severity of suspected bacterial corneal ulcers.
Study Design:
Randomized, controlled clinical trial.
Setting:
Inpatient at Siriraj Hospital.
Participants:
All patients with suspected corneal ulcers. Patients with fungal cause known before admission and an allergy to any medication, were excluded.
Intervention:
Topical ciprofloxacin 0.3 per cent or cefazolin (50 mg/ml) and fortified gentamicin (14 mg/ml) were given every 15 minutes for the first 6 hours, then every half hour on the first day, and every hour while awake till midnight until complete recovery without staining of fluorescein and no culture growth.
Main Outcome Measures:
The primary outcomes were the success rate and duration of the healing of the ulcer after treatment in each group.
Results:
Forty-one patients were enrolled. Twelve (70.6%) of 17 patients in the ciprofloxacin group were therapeutically successful while 15 (62.5%) of 24 patients in the control group showed similar outcome without a statistically significant difference. However, the mean duration for healing after treatment was not significantly different being 14.6 days in the control group and 15.6 days in the ciprofloxacin group. Visual improvement in the success cases of the control and ciprofloxacin groups was 46.7 per cent, and 66.7 per cent, respectively.
Conclusion:
Treatment with topical ciprofloxacin in suspected bacterial corneal ulcer should be considered as an alternative to standard therapy.
Related Concept Videos
Microbiome of the Eye
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
Ophthalmic Drug Delivery Systems
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
